Aura Biosciences (AURA) Total Current Liabilities (2020 - 2026)

Aura Biosciences (AURA) has 7 years of Total Current Liabilities data on file, last reported at $16.7 million in Q1 2026.

• Quarterly Total Current Liabilities rose 37.35% year-over-year to $16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.7 million (up 37.35% YoY) and the FY2025 annual result came in at $18.4 million, up 23.27% from the prior year.
• Total Current Liabilities fell to $16.7 million in Q1 2026, from $18.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $18.8 million in Q3 2025 to a low of $5.0 million in Q1 2022.
• A 5-year average of $11.9 million and a median of $10.9 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 70.88% — and 2023, when it rose 9.33%.
• Tracing AURA's Total Current Liabilities over 5 years: stood at $10.5 million in 2022, then rose by 18.17% to $12.4 million in 2023, then gained by 20.68% to $14.9 million in 2024, then climbed by 23.27% to $18.4 million in 2025, then declined by 9.12% to $16.7 million in 2026.
• The last three Total Current Liabilities figures came in at $16.7 million (Q1 2026), $18.4 million (Q4 2025), and $18.8 million (Q3 2025), per Business Quant data.